CD274 and ovarian cancer: Durvalumab, a humanized anti-PD-L1 antibody, has shown usefulness in phase 1 studies as a combination therapy with olaparib or cediranib for recurrent ovarian cancer and is expected to have the potential for maintenance therapy.